(Q33909375)

29 July 2017

1 reference

title

Routine versus selective antifungal administration for control of fungal infections in patients with cancer. (English)

1 reference

29 July 2017

Routine versus selective antifungal administration for control of fungal infections in patients with cancer (English)

0 references

1

P C Gotzsche

1 reference

29 July 2017

H K Johansen

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

29 July 2017

2002

0 references

2000

0 references

published in

1 reference

29 July 2017

CD000026

1 reference

29 July 2017

2

1 reference

Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team

29 July 2017

4

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

A Double-Blind, Randomized, Placebo-Controlled Trial of Itraconazole Capsules as Antifungal Prophylaxis for Neutropenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Prophylactic use of fluconazole in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Congestive heart failure associated with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Interim analyses, stopping rules and data monitoring in clinical trials in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Underreporting research is scientific misconduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Multiple publication of reports of drug trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Pharmaceutical company trials and the integrity of medical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Proceedings: Causes of death in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Voriconazole versus amphotericin B in cancer patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Size of cancer clinical trials and stopping rules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Publication bias: the case for an international registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Publication bias: evidence of delayed publication in a cohort study of clinical research projects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Antifungal drug susceptibility testing. Working Party of the British Society for Antimicrobial chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000026

10.1002/14651858.CD000026

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference